Circle Pharma, Inc. Secures $100

Circle Pharma, Inc. has secured $100,000 in new investment capital from investors. This funding round marks a continued commitment to the company's innovative approach in drug discovery.

Circle Pharma, which began operations in June 2014, specializes in designing and developing bioavailable macrocyclic peptide therapeutics.

The company's core mission involves applying a computational structure-based design approach that integrates physics, chemistry, and biology.

This methodology allows Circle Pharma to develop novel, inherently permeable macrocyclic peptide drug candidates.

Their initial focus is on intracellular protein-protein interactions that play crucial roles in various cancers, forming the basis of their internal pipeline development.

Circle Pharma's unique strategy is built upon the pioneering work of its founders, who established a deep understanding and computational prediction capability for the drug-like properties of macrocycles.

This new capital infusion of $100,000 will be instrumental in advancing Circle Pharma's proprietary platform and accelerating its research and development initiatives.

The funds are expected to support the company's workflow, which includes using proprietary algorithms to design extensive virtual libraries of cell-permeable macrocyclic scaffolds.

These scaffolds are then refined with functional side chains to optimize target binding and permeability, with candidate compounds synthesized and rigorously tested.

The investment underscores confidence in Circle Pharma's innovative methodology and its potential to address challenging therapeutic targets.

The company plans to deploy these funds to further develop its internal pipeline and explore new opportunities, aiming to bring its novel macrocyclic peptide therapeutics closer to clinical application.